MedTrace Logo

L-arginine in Treatment of Intrauterine Growth Restriction

NCT03321292 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2018-08-14

No results posted yet for this study

Summary

Intrauterine growth restriction is an important problem in neonatal care. Intrauterine growth restriction (IUGR) is defined as a fetal weight below the 10th percentile for gestational age. One of the main causes of IUGR is placental insufficiency.

Nitric oxide(NO) increases placental blood flow. So,it might be useful to improve IUGR pregnancy outcome .

Conditions

  • Intrauterine Growth Restriction Asymmetrical

Interventions

DRUG

L-arginine 1000 mg and Acetylesalicylic acid75mg

l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.

DRUG

acetylsalicylic acid 75 mg

acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Hayam FA Mohammad, MD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2018-12-01
Completion
2018-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03321292 on ClinicalTrials.gov